Enhancing CAR-T Cell Therapy with CRISPR for Blood Cancer Treatment
DOI:
https://doi.org/10.58445/rars.2461Keywords:
CAR-T Cell Therapy, CRISPR, Blood CancerAbstract
Blood cancer cases, including lymphoma, leukemia, and multiple myeloma, remain a leading cause of cancer worldwide, with an estimated 1.24 million people being affected annually. Every year, approximately 700,000 people die from blood cancer, highlighting the urgent need for more effective treatments. Currently, chimeric antigen receptor (CAR) T-cell therapy is the most advanced treatment for these cases. CAR-T cell therapy involves genetically modifying patients’ T-cells to target and destroy cancer cells. Despite its success, CAR-T cell therapy faces challenges, including side effects like cytokine release syndrome and limited effectiveness against some blood cancers. CRISPR gene editing has the ability to overcome these limitations and strengthen CAR-T cell therapy, offering patients a potential solution by enhancing efficiency and precision in targeting cancer cells. Various types of CRISPR-Cas applications can be used in CAR-T cells to create effective treatment options, such as the creation of “off-the-shelf” allogeneic cells. This review will discuss current issues of blood cancer treatments and how CRISPR can be utilized in next-generation CAR-T cell therapies to improve T-cell engineering, strengthen resistance to tumors, and incorporate safety mechanisms to reduce side effects.
References
American Cancer Society Medical and Editorial Content Team. (2024, November 11). Car T-cell therapy and its side effects. American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html
Bristol Myers Squibb. (2018, November 27). Blood cancer infographic. https://www.bms.com/assets/bms/us/en-us/pdf/Disease-State-Info/blood-cancers-at-a-glance.pdf
Chen, T., Wang, M., Chen, Y., & Liu, Y. (2024). Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer cell international, 24(1), 133. https://doi.org/10.1186/s12935-024-03315-3
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 543(7643), 113–117. https://doi.org/10.1038/nature21405
Feng, X., Li, Z., Liu, Y., Chen, D., & Zhou, Z. (2024). CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications. Experimental hematology & oncology, 13(1), 102. https://doi.org/10.1186/s40164-024-00570-y
Gostimskaya, I. (2022). CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing. Biochemistry. Biokhimiia, 87(8), 777–788. https://doi.org/10.1134/S0006297922080090
Lonez, C., & Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells, 13(2), 146–146. https://doi.org/10.3390/cells13020146
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, W., Dillon, M., Butz, E., Ying, W., Balakumaran, A., & Kumar, S. K. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature medicine, 29(2), 422–429. https://doi.org/10.1038/s41591-022-02182-7
Memorial Sloan Kettering Cancer Center. (2023, January 23). Off-the-Shelf CAR T Cell Therapy for Multiple Myeloma Shows Promise. www.mskcc.org.https://www.mskcc.org/news/shelf-car-cell-therapy-multiple-myeloma-shows-promise
Phillips, C. (2023, September 27). Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers. One CAR T-Cell Therapy for Blood Cancers? https://www.cancer.gov/news-events/cancer-currents-blog/2023/universal-car-t-cell-blood-cancer#:~:text=It%20involves%20genetically%20manipulating%20T,an%20antigen%2C%20and%20kill%20them
Prillaman, M. (2024, June 10). What is CRISPR? A bioengineer explains. News.stanford.edu; Stanford Report. https://news.stanford.edu/stories/2024/06/stanford-explainer-crispr-gene-editing-and-beyond
Roberts, R. (2024, June 21). CRISPR Clinical Trials to Follow in 2024 and Beyond. Synthego. https://www.synthego.com/blog/crispr-clinical-trials-2024
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific reports, 7(1), 737. https://doi.org/10.1038/s41598-017-00462-8
Song, P., Zhang, Q., Xu, Z., Shi, Y., Jing, R., & Luo, D. (2024). CRISPR/Cas-based CAR-T cells: production and application. Biomarker Research, 12(1). https://doi.org/10.1186/s40364-024-00602-z
Tao, R., Han, X., Bai, X., Yu, J., Ma, Y., Chen, W., Zhang, D., & Li, Z. (2024). Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1354825
Wei, W., Chen, Z.-N., & Wang, K. (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences, 24(15), 12317. https://doi.org/10.3390/ijms241512317
Yale Medicine. (2022, June 28). Blood cancers. https://www.yalemedicine.org/conditions/blood-cancers#:~:text=Blood%20cancers%20account%20for%20about,of%20all%20cancers%20in%20children
Zhang, M., Eshraghian, E. A., Jammal, O. A., Zhang, Z., & Zhu, X. (2021). CRISPR technology: The engine that drives cancer therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 133, 111007. https://doi.org/10.1016/j.biopha.2020.111007
Additional Files
Posted
Categories
License
Copyright (c) 2025 Hasmik Arutyunyan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.